Neil Scolding
USERN Advisory Board
Biography:
Neil Scolding is the Burden Professor and Director of the Bristol Institute of Clinical Neurosciences; he is currently based at Learning and Research, Southmead Hospital.He trained in Neurology in Cardiff, in Cambridge, and at the National Hospital for Neurology and Neurosurgery, Queen Square, and was a University Lecturer and Consultant Neurologist in Cambridge before coming to Bristol as the Foundation Burden chairholder in 1999.
Research Interest:
Neil has a clinical and research interest in the biology of multiple sclerosis and in particular in the clinical and experimental exploration of cell-based treatments designed to protect and repair the brain and spinal cord in patients.
Appointments:
Burden Professor of Clinical Neurosciences, Hon. Consultant Neurologist
Director, University of Bristol Institute of Clinical Neurosciences, Southmead Hospital, Bristol;
Director, Burden Neurological Institute; Director, bristol neuroscience
Education:
Medical education: Welsh National School of Medicine, Cardiff (1976 - 1982)
Qualifications, degrees: BSc (Hons), 1979 (1st Class); MB BCh, 1982; MRCP (UK), 1986;
PhD, University of Wales, 1991; FRCP, 1999
Neurology training: University of Wales, Cardiff; Addenbrooke's Hospital, Cambridge, &
National Hospital for Neurology, Queen Square & Maida Vale, London
1995-1999 - MRC Clinician Scientist Fellow, then University Lecturer; & Hon. Cons Neurologist - Neurology unit & MRC Centre for Brain Repair, Addenbrooke's Hospital, Cambridge; and The Bedford Hospitals
Awards and Grants, past 10 years:
2007
Burden Trust: Research grant supporting BNI Directorship - 3yrs; £240,000
John James Foundation: Stem Cell Lab conversion - 10yrs; £85,000
Serono: MS Clinical Research Centre - 10yrs; £100,000
The Myelin Project: Stem Cells and Myelin Repair - 1yr; £60,000
2008
King Kollakis Trust: MS Research Grant - 1yr; £60,000
Silverman Foundation: MS Stem Cell Research Grant - 5yrs; £300 000
Ataxia UK (Joint application with Dr A Wilkins) – 3 yrs; £157 185
2009
Patrick Berthoud Trust (Fellowship to Dr E Mallam) – 2 yrs; £100,000
2010
University of Bristol Research and Development Office/legacies – 3yrs, £100,000
Catholic Bishops of England and Wales: grant donation - £25,000
2011
Silverman Foundation, USA - $1.1m
2012
MRC, Bone marrow stem cell research, £450 000
MRC Bone marrow stem cell trial: back tranlsational studies £300,000
MS Trust; MRI scanning for cell therapy trial in MS £150 000
2013
Biogen, Novartis, Genzyme, Teva: combined grants of approx. £400,000 for new Southmead MS CRC
MRC Pre-clinical In-vivo Functional Imaging for Translational Regenerative Medicine [co-app’t £2.7m]
Publications:
Over 200 publications, inc. various research papers largely on the subjects of MS, oligodendrocyte biology, stem cells, and inflammatory brain disease, including Nature, The Lancet, Annals of Neurology, Brain, Glia, etc.; and four books (Butterworth-Heinemann & CUP): Immunological and Inflammatory Disorders of the Central Nervous
System; New Treatments in Neurology; The A-Z of Neurology and Multiple Sclerosis.
Selected papers:
1. Scolding N, Houston A, Linington C, Morgan B, Campbell K, Compston A Oligodendrocytes activate complement but resist lysis by vesicular removal of membrane attack complexes. Nature (1989) 339, 620-22.
2. Moreau T, etc, Scolding N, Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 344: 298-301
3. Scolding NJ, et al. An adult human oligodendrocyte progenitor. Neuroreport (1995) 6: 441-445
4. NJ Scolding et al. Oligodendrocyte progenitors are present in normal adult human tissue and in multiple sclerosis lesions (1998). Brain 121:2221-8
5. Scolding NJ et al. Aβ-related angiitis: primary angiitis of the CNS associated with CAA Brain (2005) 128:500-15.
6. Joseph F and Scolding NJ. CNS lupus - a study of 41 patients. Neurology. 2007 69:644-54.
7. Kemp,K. et al. MSC-secreted SOD promotes cerebellar neuronal survival. J Neurochem. 2010 114:1569-80
8. D Wraith, R.Pope, H.Butzkueven, H.Holder, P.Lowrey, M.Day, A.Gundlach, T.Kilpatrick, N. Scolding, and D.Wynick. A role for galanin in human and experimental inflammatory demyelination. PNAS (2009) 106:15466-71
9. Rice CM, Mallam E, Whone A, Walsh P, Brooks D, Kane N, Butler S, Marks D, Scolding N. Safety and feasibility of autologous BM cellular therapy in relapsing-progressive MS. Clin Pharmacol Ther. 2010 87:679-85.
10. Fusion between human mesenchymal stem cell and rodent cerebellar Purkinje cells. Kemp K, Gordon D, Wraith DC, Mallam E, Hartfield E, Uney J, Wilkins A, Scolding N. Neuropathol Appl Neurobiol. 2010 Sep 3 in press 2010
11. The MS risk sharing scheme. Scolding N. BMJ. 2010 Jun 3;340:c2882. doi: 10.1136/bmj.c2882
12. Kemp K, Mallam E, Hares K, Witherick J, Scolding N, Wilkins A. Mesenchymal stem cells restore frataxin expression and increase H2O2 scavenging enzymes in Friedreich ataxia fibroblasts. PLoS One. Epub 2011 Oct 7.
13. Bennetto L, Burrow J, Sakai H, Cobby J, Robertson NP, Scolding N. The relationship between relapse, impairment and disability in multiple sclerosis. Mult Scler. 2011 Oct;17(10):1218-24. Epub 2011 May 26.
14. Kemp K, Gray E, Wilkins A, Scolding N. Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum Brain, 135, 2962-72, 2012
15. Rice CM, Kemp, K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis and other neurodegenerative diseases. [Invited Review] Lancet. 2013; 382, 1204 - 1213
Neil Scolding is the Burden Professor and Director of the Bristol Institute of Clinical Neurosciences; he is currently based at Learning and Research, Southmead Hospital.He trained in Neurology in Cardiff, in Cambridge, and at the National Hospital for Neurology and Neurosurgery, Queen Square, and was a University Lecturer and Consultant Neurologist in Cambridge before coming to Bristol as the Foundation Burden chairholder in 1999.
Research Interest:
Neil has a clinical and research interest in the biology of multiple sclerosis and in particular in the clinical and experimental exploration of cell-based treatments designed to protect and repair the brain and spinal cord in patients.
Appointments:
Burden Professor of Clinical Neurosciences, Hon. Consultant Neurologist
Director, University of Bristol Institute of Clinical Neurosciences, Southmead Hospital, Bristol;
Director, Burden Neurological Institute; Director, bristol neuroscience
Education:
Medical education: Welsh National School of Medicine, Cardiff (1976 - 1982)
Qualifications, degrees: BSc (Hons), 1979 (1st Class); MB BCh, 1982; MRCP (UK), 1986;
PhD, University of Wales, 1991; FRCP, 1999
Neurology training: University of Wales, Cardiff; Addenbrooke's Hospital, Cambridge, &
National Hospital for Neurology, Queen Square & Maida Vale, London
1995-1999 - MRC Clinician Scientist Fellow, then University Lecturer; & Hon. Cons Neurologist - Neurology unit & MRC Centre for Brain Repair, Addenbrooke's Hospital, Cambridge; and The Bedford Hospitals
Awards and Grants, past 10 years:
2007
Burden Trust: Research grant supporting BNI Directorship - 3yrs; £240,000
John James Foundation: Stem Cell Lab conversion - 10yrs; £85,000
Serono: MS Clinical Research Centre - 10yrs; £100,000
The Myelin Project: Stem Cells and Myelin Repair - 1yr; £60,000
2008
King Kollakis Trust: MS Research Grant - 1yr; £60,000
Silverman Foundation: MS Stem Cell Research Grant - 5yrs; £300 000
Ataxia UK (Joint application with Dr A Wilkins) – 3 yrs; £157 185
2009
Patrick Berthoud Trust (Fellowship to Dr E Mallam) – 2 yrs; £100,000
2010
University of Bristol Research and Development Office/legacies – 3yrs, £100,000
Catholic Bishops of England and Wales: grant donation - £25,000
2011
Silverman Foundation, USA - $1.1m
2012
MRC, Bone marrow stem cell research, £450 000
MRC Bone marrow stem cell trial: back tranlsational studies £300,000
MS Trust; MRI scanning for cell therapy trial in MS £150 000
2013
Biogen, Novartis, Genzyme, Teva: combined grants of approx. £400,000 for new Southmead MS CRC
MRC Pre-clinical In-vivo Functional Imaging for Translational Regenerative Medicine [co-app’t £2.7m]
Publications:
Over 200 publications, inc. various research papers largely on the subjects of MS, oligodendrocyte biology, stem cells, and inflammatory brain disease, including Nature, The Lancet, Annals of Neurology, Brain, Glia, etc.; and four books (Butterworth-Heinemann & CUP): Immunological and Inflammatory Disorders of the Central Nervous
System; New Treatments in Neurology; The A-Z of Neurology and Multiple Sclerosis.
Selected papers:
1. Scolding N, Houston A, Linington C, Morgan B, Campbell K, Compston A Oligodendrocytes activate complement but resist lysis by vesicular removal of membrane attack complexes. Nature (1989) 339, 620-22.
2. Moreau T, etc, Scolding N, Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 344: 298-301
3. Scolding NJ, et al. An adult human oligodendrocyte progenitor. Neuroreport (1995) 6: 441-445
4. NJ Scolding et al. Oligodendrocyte progenitors are present in normal adult human tissue and in multiple sclerosis lesions (1998). Brain 121:2221-8
5. Scolding NJ et al. Aβ-related angiitis: primary angiitis of the CNS associated with CAA Brain (2005) 128:500-15.
6. Joseph F and Scolding NJ. CNS lupus - a study of 41 patients. Neurology. 2007 69:644-54.
7. Kemp,K. et al. MSC-secreted SOD promotes cerebellar neuronal survival. J Neurochem. 2010 114:1569-80
8. D Wraith, R.Pope, H.Butzkueven, H.Holder, P.Lowrey, M.Day, A.Gundlach, T.Kilpatrick, N. Scolding, and D.Wynick. A role for galanin in human and experimental inflammatory demyelination. PNAS (2009) 106:15466-71
9. Rice CM, Mallam E, Whone A, Walsh P, Brooks D, Kane N, Butler S, Marks D, Scolding N. Safety and feasibility of autologous BM cellular therapy in relapsing-progressive MS. Clin Pharmacol Ther. 2010 87:679-85.
10. Fusion between human mesenchymal stem cell and rodent cerebellar Purkinje cells. Kemp K, Gordon D, Wraith DC, Mallam E, Hartfield E, Uney J, Wilkins A, Scolding N. Neuropathol Appl Neurobiol. 2010 Sep 3 in press 2010
11. The MS risk sharing scheme. Scolding N. BMJ. 2010 Jun 3;340:c2882. doi: 10.1136/bmj.c2882
12. Kemp K, Mallam E, Hares K, Witherick J, Scolding N, Wilkins A. Mesenchymal stem cells restore frataxin expression and increase H2O2 scavenging enzymes in Friedreich ataxia fibroblasts. PLoS One. Epub 2011 Oct 7.
13. Bennetto L, Burrow J, Sakai H, Cobby J, Robertson NP, Scolding N. The relationship between relapse, impairment and disability in multiple sclerosis. Mult Scler. 2011 Oct;17(10):1218-24. Epub 2011 May 26.
14. Kemp K, Gray E, Wilkins A, Scolding N. Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum Brain, 135, 2962-72, 2012
15. Rice CM, Kemp, K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis and other neurodegenerative diseases. [Invited Review] Lancet. 2013; 382, 1204 - 1213
No items yet!
No items yet!